<DOC>
	<DOCNO>NCT01524991</DOCNO>
	<brief_summary>Gemcitabine plus cisplatin standard treatment advance urothelial cancer . Ipilimumab show intriguing activity neoadjuvant therapy patient clinically localized bladder cancer undergo radical cystectomy . The combination gemcitabine , cisplatin , plus ipilimumab may build chemosensitivity urothelial carcinoma produce durable response improve outcome .</brief_summary>
	<brief_title>First-Line Gemcitabine , Cisplatin + Ipilimumab Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study Gemcitabine 1000 mg/m2 Days 1 &amp; 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 ( start cycle 3 ) Treatment induction phase administer six 21-day cycle . During cycle 1 2 , gemcitabine plus cisplatin administer WITHOUT ipilimumab . During cycle 3-6 , combination therapy gemcitabine , cisplatin , plus ipilimumab administer . Patients without evidence disease progression ( irRC ) completion cycle 6 continue single-agent ipilimumab maintenance every 3 month . Karnofsky performance status ( KPS ) ≥ 80 % within 14 day prior registration protocol therapy . Life Expectancy : Not Specified Hematopoietic : - White blood cell count ( WBC ) ≥ 3.5K/mm3 - Hemoglobin ( Hgb ) ≥ 9 g/dL - Platelets ≥ 100K/mm3 - Absolute neutrophil count ( ANC ) ≥ 1.5k/mm3 Hepatic : - Bilirubin ≤ 1.5 time x Upper Limit Normal ( ULN ) ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) - Aspartate aminotransferase ( AST , SGOT ) ≤ 2.5 x ULN . NOTE : If patient liver metastasis present , ≤ 5 x ULN Renal : - Calculated creatinine clearance ≥ 55 cc/min use Cockcroft-Gault formula Cardiovascular : Not Specified</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological cytological proof urothelial carcinoma urethra , bladder , ureter , renal pelvis . Advanced ( clinical stage T4b , unresectable ) metastatic disease . Prior radiation therapy allow &lt; 25 % bone marrow . Age &gt; 18 year time consent . Written inform consent HIPAA authorization release personal health information . Females must pregnant breastfeeding . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start ipilimumab . Men father potential must use adequate method contraception avoid conception throughout study [ 26 week last dose investigational product ] manner risk pregnancy minimize . Prior Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis ) . Patients immune disorder enrol without discussion principal investigator . No active CNS metastasis . Subjects neurological symptom must undergo head CT scan brain MRI exclude brain metastasis . No prior malignancy allow except cancer definitively treat risk recurrence &lt; 30 % base treat oncologist assessment . Patients may receive prior systemic chemotherapy metastatic/advanced urothelial carcinoma . Prior neoadjuvant/adjuvant therapy permit complete ≥ 12 month prior registration protocol therapy . Prior intravesical therapy permit . No treatment investigational agent within 30 day prior registration protocol therapy . No underlying medical psychiatric condition , opinion investigator make administration ipilimumab hazardous obscure interpretation AEs , condition associate frequent diarrhea . No nononcology vaccine therapy use prevention infectious disease ( 1 month dose ipilimumab ) . No history prior treatment ipilimumab prior CD137 agonist CTLA 4 inhibitor agonist . No known active chronic infection HIV , Hepatitis B , Hepatitis C. No clinically significant infection judge treat investigator . No chronic systemic corticosteroid ( define equivalent prednisone ≥ 20 mg PO daily &gt; 6 month past year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>